YU89701A - Substituisani derivati purina kao inhibitori adhezije ćelije - Google Patents
Substituisani derivati purina kao inhibitori adhezije ćelijeInfo
- Publication number
- YU89701A YU89701A YU89701A YUP89701A YU89701A YU 89701 A YU89701 A YU 89701A YU 89701 A YU89701 A YU 89701A YU P89701 A YUP89701 A YU P89701A YU 89701 A YU89701 A YU 89701A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- compounds
- cell
- formula
- cell adhesion
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenja formule (I) u kojoj B, D, E, G, X, Y, Z, R1, R2 i s imaju značenja koja su navedena u patentnim zahtevima, njihove fiziološki prihvatljive soli i njihove prolekove. Jedinjenja formule (I) su korisna farmakološki aktivna jedinjenja. Ona su antagonisti vitronektin receptora i inhibitori adhezije ćelije i pogodni su za terapiju i profilaksu bolesti koje su zasnovane na interakciji izmedju vitronektin receptora i njihovih liganda u procesima ćelija-ćelija ili ćelija-matriks interakcije ili koje mogu svojim uticajem na takve interakcije da dovedu do prevencije, poboljšanja ili izlečenja. Na primer, mogu se davati za inhibiciju resorpcije kostiju do koje dovode osteoklasti i na taj način za lečenje i prevenciju osteoporoze ili za inhibiciju neželjenih angiogeneza ili proliferaciju ćelija krvnih sudova glatke muskulature. Pronalazak se dalje odnosi na postupak za dobijanje jedinjenja formule (I), njihovu upotrebu posebno kao aktivnih sastojaka u lekovima i farmaceutskim kompozicijama koje ih uključuju.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99112637A EP1065208A1 (en) | 1999-07-02 | 1999-07-02 | Substituted purine derivatives as inhibitors of cell adhesion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU89701A true YU89701A (sh) | 2004-09-03 |
Family
ID=8238483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU89701A YU89701A (sh) | 1999-07-02 | 2001-12-19 | Substituisani derivati purina kao inhibitori adhezije ćelije |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6747016B1 (sh) |
| EP (2) | EP1065208A1 (sh) |
| JP (1) | JP2003503497A (sh) |
| KR (1) | KR20020015997A (sh) |
| CN (1) | CN1171888C (sh) |
| AR (1) | AR034242A1 (sh) |
| AT (1) | ATE262528T1 (sh) |
| AU (1) | AU774382B2 (sh) |
| BG (1) | BG106229A (sh) |
| BR (1) | BR0012050A (sh) |
| CA (1) | CA2376673A1 (sh) |
| CZ (1) | CZ20014553A3 (sh) |
| DE (1) | DE60009296T2 (sh) |
| EA (1) | EA005372B1 (sh) |
| EE (1) | EE200100713A (sh) |
| ES (1) | ES2219353T3 (sh) |
| HU (1) | HUP0300183A3 (sh) |
| IL (1) | IL147245A0 (sh) |
| MX (1) | MXPA01013241A (sh) |
| MY (1) | MY122631A (sh) |
| NO (1) | NO20016403L (sh) |
| NZ (1) | NZ516095A (sh) |
| PL (1) | PL352281A1 (sh) |
| SK (1) | SK18792001A3 (sh) |
| TR (1) | TR200103858T2 (sh) |
| TW (1) | TWI229080B (sh) |
| UA (1) | UA72923C2 (sh) |
| WO (1) | WO2001002399A1 (sh) |
| YU (1) | YU89701A (sh) |
| ZA (1) | ZA200200017B (sh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10042655A1 (de) * | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
| FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| ES2684821T3 (es) | 2005-12-29 | 2018-10-04 | Lexicon Pharmaceuticals, Inc. | Derivados de aminoácidos multicíclicos y métodos de su uso |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| CN107450106A (zh) * | 2017-09-28 | 2017-12-08 | 北京小米移动软件有限公司 | 饮水安全提示方法、装置及智能水杯 |
| WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741796A (en) * | 1994-05-27 | 1998-04-21 | Merck & Co., Inc. | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption |
| EP0934305A4 (en) * | 1996-08-29 | 2001-04-11 | Merck & Co Inc | INTEGRINE ANTAGONISTS |
| AU717283B2 (en) * | 1996-10-30 | 2000-03-23 | Merck & Co., Inc. | Integrin antagonists |
| DE19653646A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
| AU729869B2 (en) * | 1997-01-17 | 2001-02-15 | Merck & Co., Inc. | Integrin antagonists |
| WO1999037621A1 (en) * | 1998-01-23 | 1999-07-29 | Aventis Pharma Deutschland Gmbh | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| WO1999038621A1 (en) | 1998-01-28 | 1999-08-05 | Danmist Aps | Method of piezoelectrically atomising and pumping fluids and piezoelectric fluid atomising and pumping device |
-
1999
- 1999-07-02 EP EP99112637A patent/EP1065208A1/en not_active Withdrawn
-
2000
- 2000-06-26 AU AU55349/00A patent/AU774382B2/en not_active Ceased
- 2000-06-26 CZ CZ20014553A patent/CZ20014553A3/cs unknown
- 2000-06-26 MX MXPA01013241A patent/MXPA01013241A/es active IP Right Grant
- 2000-06-26 HU HU0300183A patent/HUP0300183A3/hu unknown
- 2000-06-26 US US10/030,290 patent/US6747016B1/en not_active Expired - Fee Related
- 2000-06-26 SK SK1879-2001A patent/SK18792001A3/sk unknown
- 2000-06-26 TR TR2001/03858T patent/TR200103858T2/xx unknown
- 2000-06-26 CN CNB008121001A patent/CN1171888C/zh not_active Expired - Fee Related
- 2000-06-26 NZ NZ516095A patent/NZ516095A/en unknown
- 2000-06-26 JP JP2001507836A patent/JP2003503497A/ja not_active Withdrawn
- 2000-06-26 IL IL14724500A patent/IL147245A0/xx unknown
- 2000-06-26 EP EP00940406A patent/EP1196416B1/en not_active Expired - Lifetime
- 2000-06-26 CA CA002376673A patent/CA2376673A1/en not_active Abandoned
- 2000-06-26 PL PL00352281A patent/PL352281A1/xx not_active Application Discontinuation
- 2000-06-26 EE EEP200100713A patent/EE200100713A/xx unknown
- 2000-06-26 DE DE60009296T patent/DE60009296T2/de not_active Expired - Fee Related
- 2000-06-26 AT AT00940406T patent/ATE262528T1/de not_active IP Right Cessation
- 2000-06-26 EA EA200200121A patent/EA005372B1/ru not_active IP Right Cessation
- 2000-06-26 ES ES00940406T patent/ES2219353T3/es not_active Expired - Lifetime
- 2000-06-26 BR BR0012050-2A patent/BR0012050A/pt not_active IP Right Cessation
- 2000-06-26 UA UA2002020851A patent/UA72923C2/uk unknown
- 2000-06-26 WO PCT/EP2000/005921 patent/WO2001002399A1/en not_active Application Discontinuation
- 2000-06-26 KR KR1020017016962A patent/KR20020015997A/ko not_active Application Discontinuation
- 2000-06-29 AR ARP000103314A patent/AR034242A1/es not_active Application Discontinuation
- 2000-06-29 MY MYPI20002961A patent/MY122631A/en unknown
- 2000-09-01 TW TW089117924A patent/TWI229080B/zh not_active IP Right Cessation
-
2001
- 2001-12-17 BG BG106229A patent/BG106229A/bg unknown
- 2001-12-19 YU YU89701A patent/YU89701A/sh unknown
- 2001-12-28 NO NO20016403A patent/NO20016403L/no not_active Application Discontinuation
-
2002
- 2002-01-02 ZA ZA200200017A patent/ZA200200017B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2000001842A0 (en) | Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists. | |
| BG104630A (en) | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | |
| CA2225366A1 (en) | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them | |
| HUP0102602A2 (hu) | Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| ATE250623T1 (de) | 4'-c-ethynyl-purin-nukleoside | |
| CA2371789A1 (en) | Novel guanidine derivatives as inhibitors of cell adhesion | |
| YU92201A (sh) | Derivati naftiridina, postupci za njihovo dobijanje, njihova upotreba i farmaceutske kompozicije koje ih uključuju | |
| ES2036926A1 (es) | "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina". | |
| AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
| YU89701A (sh) | Substituisani derivati purina kao inhibitori adhezije ćelije | |
| AR022405A1 (es) | Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos | |
| AU2674201A (en) | Thienylalanine derivatives as inhibitors of cell adhesion | |
| NO20033981L (no) | Imidazolidinderivater, deres fremstilling og deres anvendelse som antiinflammatorisk middel | |
| HK1075656A1 (en) | New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | |
| DE60138893D1 (sh) | ||
| KR100718030B1 (ko) | 변형성 관절증 치료제 | |
| DE3370625D1 (en) | Benzhydrylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| UA27738C2 (uk) | 2,3,4,5,6,7-гексагідро-1-[4-[1-[4-(2метоксифеніл)піперазиніл]]-2-фенілбутирил]-1н-азепін або його фармацевтично прийнятна кислотно-адитивна сіль, що мають властивість пов'язувати рецептор 5нт1а, спосіб (варіанти) їх одержання, фармацевтична композиція |